Antibody Biosimilars
| Project | INN | Original | Major Indications | Status | Clinical Info |
|---|---|---|---|---|---|
| CT-P39 | Omalizumab | XOLAIR® | Asthma, Urticaria | Phase3 |
|
| CT-P41 | Denosumab | PROLIA® |
Osteoporosis, Bone Loss | Phase3 |
|
| CT-P43 | Ustekinumab | STELARA |
Psoriasis, Crohn's disease, Ulcerative colitis | Phase3 |
|
| CT-P42 | Aflibercept | EYLEA |
Diabetic Macular Edema | Phase3 |
|
| CT-P47 | Tocilizumab | ACTEMRA |
Rheumatoid arthritis | Phase3 |
|
| CT-P53 | Ocrelizumab | OCREVUS |
Multiple sclerosis | Phase3 |
|
- * Registered trademarks of reference products
- XOLAIR® is a registered trademark of NOVARTIS
- AVASTIN® is a registered trademark of GENENTECH
- PROLIA® is a registered trademark of AMGEN
- STELARA® is a registered trademark of JANSSEN
- EYLEA® is a registered trademark of REGENERON and BAYER
- ACTEMRA® is a registered trademark of CHUGAI SEIYAKU
New Antibodies
| Project | Indications | Status | Clinical Info |
|---|---|---|---|
| CT-P27 | Pandemic·Seasonal influenza | Phase2 |
